SEC Form 4 · accession 0001493152-26-033634
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samir Rashmikant Patel
Director · 10% Owner
Period of report
Jul 7, 2026
Accepted (ET)
Jul 17, 2026 · 6:03 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001541157
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary Shares representing Ordinary Shares | Jul 7, 2026 | M | 1,209 | $8.00 | A | 76,976 | I | PranaBio Investments LLC |
| American Depositary Shares representing Ordinary Shares | Jul 7, 2026 | M | 15,466 | $0.0004 | A | 92,442 | I | PranaBio Investments LLC |
| American Depositary Shares representing Ordinary Shares | Jul 7, 2026 | M | 5,799 | $0.0004 | A | 98,241 | I | PranaBio Investments LLC |
| American Depositary Shares representing Ordinary Shares | holding | — | — | — | 3,566 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrant to purchase American Depositary SharesF1,F2 | $8.00 | Jul 7, 2026 | M | 1,209 | A | Oct 6, 2023 | — | American Depositary Shares representing Ordinary Shares | 1,209 | 0 | I |
| Pre-Funded Warrant to purchase ADSsF4,F3,F2 | $0.0004 | Jul 7, 2026 | M | 15,466 | A | — | — | American Depositary Shares representing Ordinary Shares | 15,466 | 0 | I |
| Pre-Funded Warrant to purchase ADSsF5,F3,F2 | $0.0004 | Jul 7, 2026 | M | 5,799 | A | — | — | American Depositary Shares representing Ordinary Shares | 5,799 | 0 | I |
Explanation of responses
- F1Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share.
- F2The pre-funded warrants remain exercisable until fully exercised.
- F3The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
- F4The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16.
- F5On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs.